Chonluten (EDG)

EDG Tripeptide | Bronchial/Lung Bioregulator

Weight: 319 Da
Half-life: Minutes (short peptide); effects persist via epigenetic changes
Chain: 3 amino acids
4 studies
2022 latest
Moderate Research
Dose 10-20 mg daily
Frequency Once daily for 10-20 consecutive days
Cycle 10-20 days per cycle
Storage Capsules: room temperature; Injectable lyophilized: 2-8°C; Reconstituted: 2-8°C refrigerated

Community Research

Join others researching Chonluten — share findings, ask questions, and learn from real experiences

View Results Aggregated community findings
Discussion Questions & experiences
Submit Your Findings Contribute your research data

Chonluten is a Khavinson bioregulator tripeptide (EDG) derived from respiratory lung tissue. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it targets the bronchopulmonary system with secondary activity in the GI tract. Research shows it regulates genes related to inflammation, antioxidant activity, and proliferation responses. Chonluten inhibits TNF production in monocytes and has been studied as a potential geroprotective agent that may support lung function in conditions like COPD.

Mechanism of Action

Chonluten works through epigenetic regulation, penetrating cell and nuclear membranes to bind promoter or suppressor regions of DNA and modulate transcriptional control. It regulates genes including c-Fos, HSP70 (heat-shock protein), SOD (superoxide dismutase), COX-2, and TNF-alpha related to oxidative stress and proliferative regulation. The peptide inhibits TNF production in monocytes exposed to pro-inflammatory LPS, promoting attenuation of inflammatory action through TNF tolerance mechanisms.

01 Normalizes respiratory system function
02 Regulates protein synthesis in lung tissue
03 Inhibits inflammatory TNF production
04 Restores lung alveolar tissues
05 Maintains bronchial mucous membranes
06 Supports antioxidant gene expression
07 May slow cell aging (geroprotective)
08 Modulates mucosal function

Molecular Data

Molecular Weight
319 Da
Chain Length
3 amino acids
Type
Tripeptide bioregulator
Amino Acid Sequence
One-letter: EDG
H₂N
E 1
O ‖ C
N
D 2
O ‖ C
N
H
G 3
COOH
Glu
1

Glutamic Acid

Position 1

Asp
2

Aspartic Acid

Position 2

Gly
3

Glycine

Position 3

N-terminus C-terminus
Hydrophobic
Polar
Positive (+)
Negative (-)
Modified

Research Indications

Respiratory Support
Bronchial Function effective

Normalizes respiratory system function through gene expression regulation.

Lung Tissue Health effective

Restores and maintains lung alveolar tissues and bronchial mucous membranes.

COPD Support moderate

May modulate mucosal function in chronic obstructive pulmonary disease.

Anti-Inflammatory
TNF Modulation effective

Inhibits TNF production in monocytes, reducing inflammatory responses.

Oxidative Stress moderate

Supports SOD and antioxidant gene expression.

Anti-Aging
Geroprotection moderate

Researched as potential agent that may slow cell aging.

Gene Expression Regulation moderate

Modulates c-Fos and proliferative gene activity.

Dosing Protocols

Available in capsule form for oral administration. As a tripeptide, Chonluten has favorable permeability across cellular compartments. Typical protocol involves 10-20 day cycles.

GoalDoseFrequencyRoute
Standard protocol10-20 mgDaily for 10-20 daysOral capsules
Maintenance10 mg2-3 cycles yearlyOral capsules

Interactions

++
Bronchogen
Related respiratory bioregulators; complementary mechanisms.
synergistic
++
Epitalon
Often combined in comprehensive anti-aging Khavinson protocols.
synergistic
+
Crystagen
Both have immune-modulating properties; different tissue targets.
compatible
+
BPC-157
Both support mucosal health through different mechanisms.
compatible

What to Expect

During cycle
Gene expression modulation and anti-inflammatory effects begin
Post-cycle
Effects persist due to epigenetic changes
Weeks-Months
Respiratory function improvements
Long-term
Cumulative benefits with periodic cycles

Side Effects & Safety

Common Side Effects

  • Generally well-tolerated
  • Minimal side effects reported

Stop Signs - Discontinue if:

  • Allergic reactions
  • Unusual respiratory symptoms

Contraindications

  • Active respiratory emergencies (seek medical care)
  • Known hypersensitivity
  • Pregnancy or breastfeeding

Quality Checklist

Good Signs

  • White powder or capsules
  • Clear solution if reconstituted
  • Proper packaging and labeling

Warning Signs

  • Unknown source or purity

Bad Signs

  • Discoloration
  • Unusual odor
  • Damaged packaging

References

  • Peptides Regulating Proliferative Activity and Inflammatory Pathways in THP-1 Cells
    PMC/NCBI (2022)

    Chonluten tripeptide inhibits TNF production in monocytes exposed to pro-inflammatory LPS.

  • Chonluten and Gene Expression Regulation
    Advances in Gerontology (2018)

    Chonluten regulates c-Fos, HSP70, SOD, COX-2, and TNF-alpha gene expression.

  • Bronchial Bioregulator Peptides
    Bulletin of Experimental Biology and Medicine (2016)

    Short peptides derived from bronchial tissue regulate protein synthesis in lung cells.

  • Khavinson Peptide Bioregulators
    Advances in Gerontology (2020)

    Comprehensive review of bioregulator peptides including Chonluten and their mechanisms.

Related Peptides

Bronchogen synergistic

Related respiratory bioregulators; complementary mechanisms.

Epitalon synergistic

Often combined in comprehensive anti-aging Khavinson protocols.

Crystagen compatible

Both have immune-modulating properties; different tissue targets.

BPC-157 compatible

Both support mucosal health through different mechanisms.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.